ACRS
Aclaris Therapeutics Inc
3.70$
-13.3%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | +46.1% | +11.9% | +228.8% | -55.7% | +125.4% | +37.4% | +16.3% | -83.2% | +11.4% | +28.5% | +45.4% | -29.2% | +9.0% | +12.5% | +2.6% | -9.0% | -9.5% | -3.2% | +5.2% | +1,144.6% | -59.2% | -67.4% | -26.1% | +396.6% | +89.3% | -86.4% | +15.3% | +57.1% | +111.9% | -84.2% | +22.1% | +85.6% | -60.7% | +54.1% | -18.4% | – | |
| – | – | – | +16.8% | -97.0% | +66.4% | +28.2% | +22.1% | +1.0% | +194.1% | -20.9% | -2.7% | -69.4% | +24.3% | +23.6% | +9.5% | -14.4% | +8.2% | -6.5% | +5.1% | -13.0% | +4.5% | +0.5% | -7.5% | +669.9% | -81.6% | +23.4% | -14.8% | +414.6% | -21.5% | -71.4% | +3.8% | +26.1% | +286.3% | -94.6% | +265.6% | -70.9% | -249.3% | – | -41.5% | – | |
| – | – | – | – | – | +6.1% | -38.4% | +1,552.3% | -82.6% | -63.2% | +1,315.0% | +39.7% | -95.0% | -56.7% | +102.9% | +376.1% | -60.4% | +13.1% | +95.6% | -2.4% | -0.2% | -37.1% | -15.3% | +54.4% | +2,246.7% | -42.2% | -89.4% | -58.0% | +293.5% | +922.2% | -95.0% | +53.6% | +126.1% | -104.6% | – | -107.7% | – | -24.0% | -23.7% | -12.7% | – | |
| – | -3.1% | +11.9% | +2.5% | +36.4% | +21.4% | +3.2% | +2.8% | +13.9% | +22.6% | +2.0% | -11.5% | -8.2% | -28.5% | -33.6% | -15.8% | -3.5% | +43.5% | -12.5% | +0.8% | +77.0% | +0.9% | +1.4% | +31.3% | +26.0% | -10.9% | +7.2% | +11.9% | -5.5% | +11.6% | -63.1% | -11.0% | -32.0% | +51.5% | +28.3% | -1.2% | +13.8% | +27.3% | -5.6% | +20.4% | – | |
| – | +28.3% | -20.6% | +11.3% | +10.2% | +18.4% | +15.8% | +5.8% | -0.7% | +1.8% | +22.4% | -2.5% | -22.7% | +6.3% | -5.6% | -10.1% | -30.7% | +26.9% | -1.5% | +21.6% | +1.9% | +16.1% | -12.2% | -0.4% | -4.3% | +22.9% | +23.0% | -17.0% | -6.8% | +20.8% | -16.7% | -30.6% | +19.0% | -12.4% | +23.9% | -12.3% | -9.6% | +14.5% | +20.9% | -10.3% | – | |
| – | +7.5% | +11.2% | +18.3% | +24.1% | +35.3% | +21.1% | +6.0% | +2.8% | +15.7% | +1.0% | -13.0% | -34.8% | -21.6% | -11.2% | -23.1% | -10.9% | +29.2% | +110.1% | -36.2% | +12.3% | +11.5% | -17.4% | +11.7% | +47.6% | +11.5% | -13.4% | +5.0% | +1.8% | -53.5% | +28.3% | -29.6% | -9.5% | +702.5% | -80.9% | -3.7% | +8.6% | +24.7% | -4.2% | +7.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +183.3% | -35.3% | +214.1% | -76.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -100.0% | – | – | – | +76.9% | -198.3% | – | – | -2,288.9% | – | – | -70.8% | -81.3% | +122.6% | -165.8% | – | – | +342.6% | -131.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.